Updating a Strategy for Histone Deacetylases and Its Inhibitors in the Potential Treatment of Cerebral Ischemic Stroke

Abstract EN

Background.

Cerebral ischemic stroke is one of the severe diseases with a pathological condition that leads to nerve cell dysfunction with seldom available therapy options.

Currently, there are few proven effective treatments available for improving cerebral ischemic stroke outcome.

However, recently, there is increasing evidence that inhibition of histone deacetylase (HDAC) activity exerts a strong protective effect in in vivo and vitro models of ischemic stroke.

Review Summary.

HDAC is a posttranslational modification that is negatively regulated by histone acetyltransferase (HATS) and histone deacetylase.

Based on function and DNA sequence similarity, histone deacetylases (HDACs) are organized into four different subclasses (I-IV).

Modifications of histones play a crucial role in cerebral ischemic affair development after translation by modulating disrupted acetylation homeostasis.

HDAC inhibitors (HDACi) mainly exert neuroprotective effects by enhancing histone and nonhistone acetylation levels and enhancing gene expression and protein modification functions.

This article reviews HDAC and its inhibitors, hoping to find meaningful therapeutic targets.

Conclusions.

HDAC may be a new biological target for cerebral ischemic stroke.

Future drug development targeting HDAC may make it a potentially effective anticerebral ischemic stroke drug.